vs
Side-by-side financial comparison of First Western Financial Inc (MYFW) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
First Western Financial Inc is the larger business by last-quarter revenue ($27.5M vs $18.6M, roughly 1.5× SCYNEXIS INC). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 10.0%).
The Western Union Company is an American multinational financial services corporation headquartered in Denver, Colorado.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
MYFW vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $18.6M |
| Net Profit | — | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | — | 65.7% |
| Revenue YoY | — | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $0.63 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.5M | — | ||
| Q4 25 | $26.7M | $18.6M | ||
| Q3 25 | $26.3M | $334.0K | ||
| Q2 25 | $24.2M | $1.4M | ||
| Q1 25 | $24.8M | $257.0K | ||
| Q4 24 | $24.3M | $977.0K | ||
| Q3 24 | $22.5M | $660.0K | ||
| Q2 24 | $22.8M | $736.0K |
| Q1 26 | — | — | ||
| Q4 25 | $3.3M | $12.3M | ||
| Q3 25 | $3.2M | $-8.6M | ||
| Q2 25 | $2.5M | $-6.9M | ||
| Q1 25 | $4.2M | $-5.4M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $2.1M | $-2.8M | ||
| Q2 24 | $1.1M | $-14.5M |
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | 56.3% | ||
| Q3 25 | 15.1% | -2516.5% | ||
| Q2 25 | 13.7% | -701.0% | ||
| Q1 25 | 21.6% | -3350.2% | ||
| Q4 24 | 16.1% | — | ||
| Q3 24 | 11.9% | -1563.6% | ||
| Q2 24 | 6.2% | -1255.0% |
| Q1 26 | — | — | ||
| Q4 25 | 12.9% | 65.7% | ||
| Q3 25 | 12.1% | -2572.2% | ||
| Q2 25 | 10.3% | -504.8% | ||
| Q1 25 | 16.9% | -2097.7% | ||
| Q4 24 | 11.3% | — | ||
| Q3 24 | 9.5% | -425.5% | ||
| Q2 24 | 4.7% | -1964.4% |
| Q1 26 | $0.63 | — | ||
| Q4 25 | $0.33 | $0.25 | ||
| Q3 25 | $0.32 | $-0.17 | ||
| Q2 25 | $0.26 | $-0.14 | ||
| Q1 25 | $0.43 | $-0.11 | ||
| Q4 24 | $0.28 | — | ||
| Q3 24 | $0.22 | $-0.06 | ||
| Q2 24 | $0.11 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $273.4M | $49.4M |
| Total Assets | $3.2B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $273.4M | — | ||
| Q4 25 | $265.6M | $49.4M | ||
| Q3 25 | $261.5M | $36.4M | ||
| Q2 25 | $258.8M | $44.5M | ||
| Q1 25 | $256.6M | $50.5M | ||
| Q4 24 | $252.3M | $55.1M | ||
| Q3 24 | $248.8M | $58.5M | ||
| Q2 24 | $246.9M | $60.4M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $59.0M | ||
| Q3 25 | $3.2B | $51.1M | ||
| Q2 25 | $3.0B | $60.7M | ||
| Q1 25 | $2.9B | $67.9M | ||
| Q4 24 | $2.9B | $90.6M | ||
| Q3 24 | $2.9B | $99.0M | ||
| Q2 24 | $2.9B | $107.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $18.4M | ||
| Q3 25 | $10.0M | $-8.7M | ||
| Q2 25 | $-9.1M | $-7.5M | ||
| Q1 25 | $8.0M | $-7.5M | ||
| Q4 24 | $606.0K | $-24.0M | ||
| Q3 24 | $18.8M | $765.0K | ||
| Q2 24 | $-11.5M | $-10.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $-9.7M | — | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $-607.0K | — | ||
| Q3 24 | $18.6M | — | ||
| Q2 24 | $-11.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | -21.6% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | -39.9% | — | ||
| Q1 25 | 28.1% | — | ||
| Q4 24 | -2.5% | — | ||
| Q3 24 | 82.3% | — | ||
| Q2 24 | -52.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 14.9% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.54× | 1.50× | ||
| Q3 25 | 3.15× | — | ||
| Q2 25 | -3.63× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | 8.83× | — | ||
| Q2 24 | -10.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MYFW
| Net Interest Income | $20.9M | 76% |
| Noninterest Income | $6.7M | 24% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
